Skip to main content
. 2019 Mar 26;11:62. doi: 10.3389/fnagi.2019.00062

Figure 1.

Figure 1

Valproic acid (VPA) improves cognitive ability in 3xTgAD mice. (A,B) Visible platform tests. The VPA-treated and control (saline-treated) Alzheimer’s disease (AD) mice exhibited a similar escape latency (A) and path length (B). (C,D) Hidden platform tests. The VPA-treated AD mice showed a shorter escape latency (C) and path length (D) on the fourth and fifth days. (E) Probe trial. The VPA-treated mice showed significantly more passing times in the target section where the platform was previously located than controls. *P < 0.05, **P < 0.01.